The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity

Kimberly Ann Bordun, Sheena Premecz, Megan daSilva, Soma Mandal, Vineet Goyal, Tamara Glavinovic, Matthew Cheung, David Cheung, Christopher W. White, Rakesh Chaudhary, Darren H. Freed, Hector R Vilarraga, Joerg Herrmann, Manish Kohli, Amir Ravandi, James Thliveris, Marshall Pitz, Pawan K. Singal, Sharon Mulvagh, Davinder S. Jassal

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The recent introduction of novel anticancer therapies, including bevacizumab (BVZ) and sunitinib (SNT), is associated with an increased risk of cardiotoxicity. However, early identification of left ventricular (LV) systolic dysfunction may facilitate dose modification and avoid the development of advanced heart failure. Using a murine model of BVZ- and SNTmediated cardiotoxicity, we investigated whether cardiac biomarkers and/or tissue velocity imaging (TVI) using echocardiography can detect early changes in cardiac function, before a decrease in LV ejection fraction is identified. A total of 75 wild-type C57Bl/6 male mice were treated with either 0.9% saline, BVZ, or SNT. Serial monitoring of blood pressure, high-sensitivity troponin I, and echocardiographic indexes were performed over a 14-day study period, after which the mice were euthanized for histological and biochemical analyses. Mice treated with either BVZ or SNT developed systemic hypertension as early as day 7, which increased by day 14. Cardiac biomarkers, specifically high-sensitivity troponin I, were not predictive of early LV systolic dysfunction. Although conventional LV ejection fraction values decreased at day 13 in mice treated with either BVZ or SNT, TVI confirmed early LV systolic dysfunction at day 8. Histological and biochemical analysis demonstrated loss of cellular integrity, increased oxidative stress, and increased cardiac apoptosis in mice treated with BVZ or SNT therapy at day 14. In a murine model of BVZ- or SNT-mediated cardiomyopathy, noninvasive assessment by TVI detected early LV systolic dysfunction before alterations in conventional echocardiographic indexes.

Original languageEnglish (US)
Pages (from-to)H692-H701
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume309
Issue number4
DOIs
StatePublished - Aug 18 2015

Fingerprint

Echocardiography
Biomarkers
Left Ventricular Dysfunction
Troponin I
Stroke Volume
Hypertension
sunitinib
Cardiotoxicity
Bevacizumab
Cardiomyopathies
Oxidative Stress
Heart Failure
Apoptosis
Therapeutics

Keywords

  • Apoptosis
  • Bevacizumab
  • Cardiac biomarkers
  • Cardio-oncology
  • Cardiotoxicity
  • Echocardiography
  • Heart failure
  • Hypertension
  • Sunitinib

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. / Bordun, Kimberly Ann; Premecz, Sheena; daSilva, Megan; Mandal, Soma; Goyal, Vineet; Glavinovic, Tamara; Cheung, Matthew; Cheung, David; White, Christopher W.; Chaudhary, Rakesh; Freed, Darren H.; Vilarraga, Hector R; Herrmann, Joerg; Kohli, Manish; Ravandi, Amir; Thliveris, James; Pitz, Marshall; Singal, Pawan K.; Mulvagh, Sharon; Jassal, Davinder S.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 309, No. 4, 18.08.2015, p. H692-H701.

Research output: Contribution to journalArticle

Bordun, KA, Premecz, S, daSilva, M, Mandal, S, Goyal, V, Glavinovic, T, Cheung, M, Cheung, D, White, CW, Chaudhary, R, Freed, DH, Vilarraga, HR, Herrmann, J, Kohli, M, Ravandi, A, Thliveris, J, Pitz, M, Singal, PK, Mulvagh, S & Jassal, DS 2015, 'The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity', American Journal of Physiology - Heart and Circulatory Physiology, vol. 309, no. 4, pp. H692-H701. https://doi.org/10.1152/ajpheart.00172.2015
Bordun, Kimberly Ann ; Premecz, Sheena ; daSilva, Megan ; Mandal, Soma ; Goyal, Vineet ; Glavinovic, Tamara ; Cheung, Matthew ; Cheung, David ; White, Christopher W. ; Chaudhary, Rakesh ; Freed, Darren H. ; Vilarraga, Hector R ; Herrmann, Joerg ; Kohli, Manish ; Ravandi, Amir ; Thliveris, James ; Pitz, Marshall ; Singal, Pawan K. ; Mulvagh, Sharon ; Jassal, Davinder S. / The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. In: American Journal of Physiology - Heart and Circulatory Physiology. 2015 ; Vol. 309, No. 4. pp. H692-H701.
@article{2e438e6f3aa84a0e93dbea91da3d2026,
title = "The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity",
abstract = "The recent introduction of novel anticancer therapies, including bevacizumab (BVZ) and sunitinib (SNT), is associated with an increased risk of cardiotoxicity. However, early identification of left ventricular (LV) systolic dysfunction may facilitate dose modification and avoid the development of advanced heart failure. Using a murine model of BVZ- and SNTmediated cardiotoxicity, we investigated whether cardiac biomarkers and/or tissue velocity imaging (TVI) using echocardiography can detect early changes in cardiac function, before a decrease in LV ejection fraction is identified. A total of 75 wild-type C57Bl/6 male mice were treated with either 0.9{\%} saline, BVZ, or SNT. Serial monitoring of blood pressure, high-sensitivity troponin I, and echocardiographic indexes were performed over a 14-day study period, after which the mice were euthanized for histological and biochemical analyses. Mice treated with either BVZ or SNT developed systemic hypertension as early as day 7, which increased by day 14. Cardiac biomarkers, specifically high-sensitivity troponin I, were not predictive of early LV systolic dysfunction. Although conventional LV ejection fraction values decreased at day 13 in mice treated with either BVZ or SNT, TVI confirmed early LV systolic dysfunction at day 8. Histological and biochemical analysis demonstrated loss of cellular integrity, increased oxidative stress, and increased cardiac apoptosis in mice treated with BVZ or SNT therapy at day 14. In a murine model of BVZ- or SNT-mediated cardiomyopathy, noninvasive assessment by TVI detected early LV systolic dysfunction before alterations in conventional echocardiographic indexes.",
keywords = "Apoptosis, Bevacizumab, Cardiac biomarkers, Cardio-oncology, Cardiotoxicity, Echocardiography, Heart failure, Hypertension, Sunitinib",
author = "Bordun, {Kimberly Ann} and Sheena Premecz and Megan daSilva and Soma Mandal and Vineet Goyal and Tamara Glavinovic and Matthew Cheung and David Cheung and White, {Christopher W.} and Rakesh Chaudhary and Freed, {Darren H.} and Vilarraga, {Hector R} and Joerg Herrmann and Manish Kohli and Amir Ravandi and James Thliveris and Marshall Pitz and Singal, {Pawan K.} and Sharon Mulvagh and Jassal, {Davinder S.}",
year = "2015",
month = "8",
day = "18",
doi = "10.1152/ajpheart.00172.2015",
language = "English (US)",
volume = "309",
pages = "H692--H701",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity

AU - Bordun, Kimberly Ann

AU - Premecz, Sheena

AU - daSilva, Megan

AU - Mandal, Soma

AU - Goyal, Vineet

AU - Glavinovic, Tamara

AU - Cheung, Matthew

AU - Cheung, David

AU - White, Christopher W.

AU - Chaudhary, Rakesh

AU - Freed, Darren H.

AU - Vilarraga, Hector R

AU - Herrmann, Joerg

AU - Kohli, Manish

AU - Ravandi, Amir

AU - Thliveris, James

AU - Pitz, Marshall

AU - Singal, Pawan K.

AU - Mulvagh, Sharon

AU - Jassal, Davinder S.

PY - 2015/8/18

Y1 - 2015/8/18

N2 - The recent introduction of novel anticancer therapies, including bevacizumab (BVZ) and sunitinib (SNT), is associated with an increased risk of cardiotoxicity. However, early identification of left ventricular (LV) systolic dysfunction may facilitate dose modification and avoid the development of advanced heart failure. Using a murine model of BVZ- and SNTmediated cardiotoxicity, we investigated whether cardiac biomarkers and/or tissue velocity imaging (TVI) using echocardiography can detect early changes in cardiac function, before a decrease in LV ejection fraction is identified. A total of 75 wild-type C57Bl/6 male mice were treated with either 0.9% saline, BVZ, or SNT. Serial monitoring of blood pressure, high-sensitivity troponin I, and echocardiographic indexes were performed over a 14-day study period, after which the mice were euthanized for histological and biochemical analyses. Mice treated with either BVZ or SNT developed systemic hypertension as early as day 7, which increased by day 14. Cardiac biomarkers, specifically high-sensitivity troponin I, were not predictive of early LV systolic dysfunction. Although conventional LV ejection fraction values decreased at day 13 in mice treated with either BVZ or SNT, TVI confirmed early LV systolic dysfunction at day 8. Histological and biochemical analysis demonstrated loss of cellular integrity, increased oxidative stress, and increased cardiac apoptosis in mice treated with BVZ or SNT therapy at day 14. In a murine model of BVZ- or SNT-mediated cardiomyopathy, noninvasive assessment by TVI detected early LV systolic dysfunction before alterations in conventional echocardiographic indexes.

AB - The recent introduction of novel anticancer therapies, including bevacizumab (BVZ) and sunitinib (SNT), is associated with an increased risk of cardiotoxicity. However, early identification of left ventricular (LV) systolic dysfunction may facilitate dose modification and avoid the development of advanced heart failure. Using a murine model of BVZ- and SNTmediated cardiotoxicity, we investigated whether cardiac biomarkers and/or tissue velocity imaging (TVI) using echocardiography can detect early changes in cardiac function, before a decrease in LV ejection fraction is identified. A total of 75 wild-type C57Bl/6 male mice were treated with either 0.9% saline, BVZ, or SNT. Serial monitoring of blood pressure, high-sensitivity troponin I, and echocardiographic indexes were performed over a 14-day study period, after which the mice were euthanized for histological and biochemical analyses. Mice treated with either BVZ or SNT developed systemic hypertension as early as day 7, which increased by day 14. Cardiac biomarkers, specifically high-sensitivity troponin I, were not predictive of early LV systolic dysfunction. Although conventional LV ejection fraction values decreased at day 13 in mice treated with either BVZ or SNT, TVI confirmed early LV systolic dysfunction at day 8. Histological and biochemical analysis demonstrated loss of cellular integrity, increased oxidative stress, and increased cardiac apoptosis in mice treated with BVZ or SNT therapy at day 14. In a murine model of BVZ- or SNT-mediated cardiomyopathy, noninvasive assessment by TVI detected early LV systolic dysfunction before alterations in conventional echocardiographic indexes.

KW - Apoptosis

KW - Bevacizumab

KW - Cardiac biomarkers

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Echocardiography

KW - Heart failure

KW - Hypertension

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84939448358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939448358&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00172.2015

DO - 10.1152/ajpheart.00172.2015

M3 - Article

C2 - 26092985

AN - SCOPUS:84939448358

VL - 309

SP - H692-H701

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 4

ER -